Mineralys CMO exercises options and sells shares

Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman exercised stock options and sold common shares in a coordinated transaction.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman exercised stock options and sold common shares in a coordinated transaction. He exercised 2,171 stock options at $16.00 per share, then sold 2,171 common shares at $30.30 per share under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following these transactions, he holds 57,733 common shares, including 638 shares from the 2023 Employee Stock Purchase Plan, and retains 15,194 stock options exercisable at $16.00 per share expiring on February 9, 2033.

Insights

Equity analyst

Routine option exercise and pre-planned sale with remaining equity stake.

Chief Medical Officer David Malcom Rodman exercised 2,171 stock options at $16.00 and sold the same number of common shares at $30.30 per share. This reflects an exercise-and-sell pattern rather than a pure open-market sale.

The sale was executed under a Rule 10b5-1 trading plan adopted on October 6, 2025, indicating it was pre-scheduled. After the transactions, Rodman still holds 57,733 common shares and 15,194 options with a $16.00 exercise price expiring on February 9, 2033, maintaining meaningful exposure to Mineralys stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,171 shares ($31K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Rodman David Malcom

Role Chief Medical Officer

Sold 2,171 shs ($66K)

Approx. gross sale proceeds $66K

Approx. exercise cost $35K

Approx. pre-tax spread $31K

Type	Security	Shares	Price	Value
Exercise	Stock Option F1, F3	2,171	$0.00	$0.00
Exercise	Common Stock F1, F2	2,171	$16.00	$35K
Sale	Common Stock F1	2,171	$30.30	$66K

Holdings After Transaction: Stock Option — 15,194 contracts (Direct); Common Stock — 57,733 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
2. F2. This balance includes 638 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.
3. F3. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Key Figures

Shares sold: 2,171 shares Sale price: $30.30 per share Options exercised: 2,171 options +5 more

8 metrics

Shares sold 2,171 shares Common stock sold in open-market transaction at $30.30 per share on July 9, 2026

Sale price $30.30 per share Price received for 2,171 common shares sold on July 9, 2026

Options exercised 2,171 options Stock options for common stock exercised at $16.00 per share on July 9, 2026

Exercise price $16.00 per share Exercise price of stock options converted into 2,171 common shares

Shares held after 57,733 shares Direct common stock ownership following reported transactions, including 638 ESPP shares

Options outstanding 15,194 options Remaining stock options with $16.00 exercise price expiring on February 9, 2033

ESPP shares included 638 shares Shares purchased under the 2023 Employee Stock Purchase Plan included in post-transaction balance

Option expiration February 9, 2033 Expiration date of the stock options with $16.00 exercise price

Key Terms

Rule 10b5-1 trading plan, Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan, stock option, vesting

4 terms

Rule 10b5-1 trading plan financial

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan financial

"includes 638 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan"

stock option financial

"The stock option vested as to 25% of the underlying shares on the first anniversary"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vesting financial

"vested as to 25% of the underlying shares on the first anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mineralys Therapeutics (MLYS) Chief Medical Officer David Malcom Rodman report in this Form 4?

He reported exercising 2,171 stock options at $16.00 per share and selling 2,171 common shares at $30.30 per share in a coordinated transaction.

How many Mineralys Therapeutics (MLYS) shares did David Malcom Rodman sell and at what price?

He sold 2,171 common shares of Mineralys Therapeutics at an average price of $30.30 per share, as part of an open-market sale transaction.

How many Mineralys Therapeutics (MLYS) shares and options does David Malcom Rodman hold after these transactions?

After the transactions, he holds 57,733 common shares, including 638 ESPP shares, and 15,194 stock options with a $16.00 exercise price expiring on February 9, 2033.

Were David Malcom Rodman’s Mineralys Therapeutics (MLYS) share sales under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025, indicating they were pre-arranged.

What options did David Malcom Rodman exercise in Mineralys Therapeutics (MLYS)?

He exercised 2,171 stock options for common stock at an exercise price of $16.00 per share; the option grant vests 25% after one year, then monthly thereafter.

What is the remaining term of David Malcom Rodman’s Mineralys Therapeutics (MLYS) stock options?

His remaining 15,194 stock options have an exercise price of $16.00 per share and an expiration date of February 9, 2033, according to the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 07:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodman David Malcom

(Last) (First) (Middle)

150 N. RADNOR CHESTER ROAD

SUITE F200

(Street)

RADNOR PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		M(1)		2,171	A	$16	59,904(2)	D
Common Stock	07/09/2026		S(1)		2,171	D	$30.3	57,733	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$16	07/09/2026		M(1)			2,171	(3)	02/09/2033	Common Stock	2,171	$0	15,194	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

2. This balance includes 638 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.

3. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)